{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:17:52Z","timestamp":1745986672902,"version":"3.40.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s43032-024-01784-5","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T18:07:04Z","timestamp":1738260424000},"page":"1676-1684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Expression of Programmed Cell Death Ligand-1 and its Relationship with Infiltration, Metastasis and Prognosis in Cervical Squamous Cell Carcinoma"],"prefix":"10.1007","volume":"32","author":[{"given":"Juyan","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3896-3742","authenticated-orcid":false,"given":"Xiujuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"1784_CR1","doi-asserted-by":"publisher","first-page":"148904","DOI":"10.1016\/j.gene.2024.148904","volume":"932","author":"R Rasizadeh","year":"2025","unstructured":"Rasizadeh R, Shiri Aghbash P, Mokhtarzadeh A, Poortahmasebi V, Ahangar Oskouee M, Sadri Nahand J, et al. Novel strategies in HPV\u201316\u2013related cervical cancer treatment: an in vitro study of combined siRNA-E5 with oxaliplatin and ifosfamide chemotherapy. Gene. 2025;932:148904.","journal-title":"Gene"},{"issue":"10","key":"1784_CR2","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.drudis.2019.07.011","volume":"24","author":"AM Almeida","year":"2019","unstructured":"Almeida AM, Queiroz JA,Sousa F, Sousa A. Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins. Drug Discov Today. 2019;24(10):2044\u201357.","journal-title":"Drug Discov Today"},{"issue":"3","key":"1784_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1784_CR4","doi-asserted-by":"publisher","first-page":"e28857","DOI":"10.1002\/jmv.28857","volume":"95","author":"C Li","year":"2023","unstructured":"Li C, Liu D,Zhao Y, Ding Y, Hua K. Diverse intratumoral heterogeneity and immune microenvironment of two HPV-related cervical cancer types revealed by single-cell RNA sequencing. J Med Virol. 2023;95(6):e28857.","journal-title":"J Med Virol"},{"issue":"10","key":"1784_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1080\/17441692.2013.850524","volume":"8","author":"JO Parkhurst","year":"2013","unstructured":"Parkhurst JO, Vulimiri M. Cervical cancer and the global health agenda: insights from multiple policy-analysis frameworks. Glob Public Health. 2013;8(10):1093\u2013108.","journal-title":"Glob Public Health"},{"issue":"4","key":"1784_CR6","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.3802\/jgo.2016.27.e43","volume":"27","author":"H Li","year":"2016","unstructured":"Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27(4):e43.","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"1784_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/ijc.34779","volume":"154","author":"S Tulsidas","year":"2024","unstructured":"Tulsidas S, Fontes F, Monteiro K,Mussa MLL, Morais AG, et al. Cervical cancer in Mozambique: clinical characteristics, treatment and survival of incident cases admitted to the Oncology Service of Maputo Central Hospital in 2016\u20132018. Int J Cancer. 2024;154(6):1019\u201328.","journal-title":"Int J Cancer"},{"key":"1784_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2147\/OTT.S433710","volume":"16","author":"V Mendieta-Carmona","year":"2023","unstructured":"Mendieta-Carmona V, Delgado-Lopez G, Reyes-Leyva J, Gutierrez-Quiroz CT, Vazquez-Zamora VJ, Picazo-Mendoza DA, et al. Galectin-9 expression is correlated to cervical squamous cell carcinoma progression and overall survival. Onco Targets Ther. 2023;16:891\u2013904.","journal-title":"Onco Targets Ther"},{"key":"1784_CR9","doi-asserted-by":"publisher","first-page":"1131803","DOI":"10.3389\/fonc.2023.1131803","volume":"13","author":"C Ming","year":"2023","unstructured":"Ming C, Bai X, Zhao L, Yu D,Wang X, Wu Y. RPL24 as a potential prognostic biomarker for cervical cancer treated by cisplatin and concurrent chemoradiotherapy. Front Oncol. 2023;13:1131803.","journal-title":"Front Oncol"},{"issue":"2","key":"1784_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jtho.2023.09.276","volume":"19","author":"X Wang","year":"2024","unstructured":"Wang X, Bai H, Wang Z,Duan J, Cai H, et al. Genetic Intratumor heterogeneity remodels the Immune Microenvironment and induces Immune Evasion in Brain Metastasis of Lung Cancer. J Thorac Oncol. 2024;19(2):252\u201372.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1784_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/cac2.12486","volume":"43","author":"X Qu","year":"2023","unstructured":"Qu X, Wang Y, Jiang Q,Ren T,Guo C, Hua K, et al. Interactions of indoleamine 2,3-dioxygenase-expressing LAMP3(+) dendritic cells with CD4(+) regulatory T cells and CD8(+) exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications. Cancer Commun (Lond). 2023;43(11):1207\u201328.","journal-title":"Cancer Commun (Lond)"},{"issue":"9","key":"1784_CR12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ijgc-2020-001649","volume":"30","author":"MR Carroll","year":"2020","unstructured":"Carroll MR, Ramalingam P, Salvo G, Fujimoto J, Solis Soto LM, Phoolcharoen N, et al. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. Int J Gynecol Cancer. 2020;30(9):1303\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"1784_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-023-02758-2","volume":"42","author":"DWS Wang","year":"2023","unstructured":"Wang DWS, He J, Sun L,Zhu H, Zhang Y, et al. FAT4 overexpression promotes antitumor immunity by regulating the beta-catenin\/STT3\/PD-L1 axis in cervical cancer. J Exp Clin Cancer Res. 2023;42(1):222.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"1784_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5114\/pjp.2023.132221","volume":"74","author":"N Sungu","year":"2023","unstructured":"Sungu N, Kiran MM. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency. Pol J Pathol. 2023;74(3):161\u201370.","journal-title":"Pol J Pathol"},{"issue":"1","key":"1784_CR15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1186\/s12885-023-11603-w","volume":"23","author":"Y Dong","year":"2023","unstructured":"Dong Y, Zheng M, Wang X, Yu C,Qin T, Shen X. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy. BMC Cancer. 2023;23(1):1097.","journal-title":"BMC Cancer"},{"key":"1784_CR16","doi-asserted-by":"publisher","first-page":"880280","DOI":"10.3389\/fphar.2022.880280","volume":"13","author":"D Zhou","year":"2022","unstructured":"Zhou D, Luo X,Zhou Z,Zeng X,Wan X, Tan C, et al. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China. Front Pharmacol. 2022;13:880280.","journal-title":"Front Pharmacol"},{"key":"1784_CR17","doi-asserted-by":"publisher","first-page":"1136437","DOI":"10.3389\/fimmu.2023.1136437","volume":"14","author":"M Gou","year":"2023","unstructured":"Gou M, Zhang Y, Wang Z, Dai G. PD-1 inhibitors-based second-line therapy for metastatic gastric cancer. Front Immunol. 2023;14:1136437.","journal-title":"Front Immunol"},{"key":"1784_CR18","doi-asserted-by":"publisher","first-page":"e934493","DOI":"10.12659\/MSM.934493","volume":"28","author":"Y Liao","year":"2022","unstructured":"Liao Y, Zhu C,Song X,Ruan J,Ding Y, Chen Y, et al. Efficacy of PD-1 inhibitor combined with Bevacizumab in Treatment of Advanced Endometrial Cancer patients with Mismatch Repair Deficiency (dMMR)\/High-Level microsatellite instability (MSI-H). Med Sci Monit. 2022;28:e934493.","journal-title":"Med Sci Monit"},{"issue":"28","key":"1784_CR19","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.12998\/wjcc.v11.i28.6841","volume":"11","author":"HY Yang","year":"2023","unstructured":"Yang HY, Du YX, Hou YJ, Lu DR, Xue P. Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: a case report. World J Clin Cases. 2023;11(28):6841\u20139.","journal-title":"World J Clin Cases"},{"issue":"11","key":"1784_CR20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.clinthera.2023.08.014","volume":"45","author":"R Sugarman","year":"2023","unstructured":"Sugarman R, Betts KA,Nie X,Hartman J, Nguyen H. Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and esophageal adenocarcinoma: analysis of number needed to treat and Number needed to harm. Clin Ther. 2023;45(11):1155\u20138.","journal-title":"Clin Ther"},{"issue":"1","key":"1784_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-23-0309","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang Y, Liu F,Du XSJ, Yu R, Li S, et al. Combination of Anti-PD-1 and electroacupuncture induces a potent Antitumor Immune response in microsatellite-stable colorectal Cancer. Cancer Immunol Res. 2024;12(1):26\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1784_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.annonc.2023.10.793","volume":"35","author":"B Lian","year":"2024","unstructured":"Lian B, Li Z, Wu N,Li M, Zheng H, et al. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann Oncol. 2024;35(2):211\u201320.","journal-title":"Ann Oncol"},{"key":"1784_CR23","doi-asserted-by":"publisher","first-page":"1393686","DOI":"10.3389\/fonc.2024.1393686","volume":"14","author":"G Chen","year":"2024","unstructured":"Chen G, Yu Y,Qi Y,Li G, Meng F, et al. Comparative analysis of PD-L1 expression and molecular alterations in primary versus metastatic lung adenocarcinoma: a real-world study in China. Front Oncol. 2024;14:1393686.","journal-title":"Front Oncol"},{"issue":"5","key":"1784_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","volume":"31","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL,Travis WD, Rekhtman N, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31(5):599\u2013608.","journal-title":"Ann Oncol"},{"issue":"8","key":"1784_CR25","first-page":"3541","volume":"9","author":"JM Wang","year":"2017","unstructured":"Wang JM, Ju BH,Pan CJ,Gu Y, Li MQ, Sun L, et al. MiR-214 inhibits cell migration, invasion and promotes the drug sensitivity in human cervical cancer by targeting FOXM1. Am J Transl Res. 2017;9(8):3541\u201357.","journal-title":"Am J Transl Res"},{"issue":"2","key":"1784_CR26","doi-asserted-by":"publisher","first-page":"e32559","DOI":"10.1097\/MD.0000000000032559","volume":"102","author":"W Zheng","year":"2023","unstructured":"Zheng W, Jin F, Wang F, Wang L, Pan Z, et al. Analysis of eEF1A2 gene expression and copy number in cervical carcinoma. Med (Baltim). 2023;102(2):e32559.","journal-title":"Med (Baltim)"},{"issue":"10","key":"1784_CR27","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/jog.13411","volume":"43","author":"W Yang","year":"2017","unstructured":"Yang W, Lu YP, Yang YZ,Kang JR, Jin YD, Wang HW. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res. 2017;43(10):1602\u201312.","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"1784_CR28","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","volume":"29","author":"A Ray","year":"2015","unstructured":"Ray A, Das DS,Song Y, Richardson P, Munshi NC,Chauhan D, et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia. 2015;29(6):1441\u20134.","journal-title":"Leukemia"},{"issue":"4","key":"1784_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1084\/jem.20102548","volume":"208","author":"Y Li","year":"2011","unstructured":"Li Y, Wang Q, Mariuzza RA. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med. 2011;208(4):703\u201314.","journal-title":"J Exp Med"},{"issue":"4","key":"1784_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nm.2106","volume":"16","author":"EA Said","year":"2010","unstructured":"Said EA, Dupuy FP,Trautmann L, Zhang Y, Shi Y, El-Far M, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4\u2009+\u2009T cell activation during HIV infection. Nat Med. 2010;16(4):452\u20139.","journal-title":"Nat Med"},{"issue":"8","key":"1784_CR31","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi J, Wada Y, Matsumoto K,Azuma M,Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2007;56(8):1173\u201382.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1784_CR32","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ijc.25397","volume":"128","author":"F Shi","year":"2011","unstructured":"Shi F, Shi M, Zeng Z,Qi RZ,Liu ZW, Zhang JY, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128(4):887\u201396.","journal-title":"Int J Cancer"},{"issue":"1","key":"1784_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1399-0039.2006.00701.x","volume":"69","author":"J Sun","year":"2007","unstructured":"Sun J, Xu K, Wu C,Wang Y,Hu Y, Zhu Y, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 2007;69(1):19\u201327.","journal-title":"Tissue Antigens"},{"issue":"12","key":"1784_CR34","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.oraloncology.2011.08.007","volume":"47","author":"YA Cho","year":"2011","unstructured":"Cho YA, Yoon HJ, Lee JI,Hong SP, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47(12):1148\u201353.","journal-title":"Oral Oncol"},{"key":"1784_CR35","doi-asserted-by":"crossref","unstructured":"Jahn SW, Plass M, Moinfar F. Digital Pathology: advantages, limitations and emerging perspectives. J Clin Med 2020; 9(11).","DOI":"10.3390\/jcm9113697"},{"issue":"2","key":"1784_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14791\/btrt.2021.0032","volume":"10","author":"H Go","year":"2022","unstructured":"Go H. Digital Pathology and Artificial Intelligence Applications in Pathology. Brain Tumor Res Treat. 2022;10(2):76\u201382.","journal-title":"Brain Tumor Res Treat"},{"issue":"8","key":"1784_CR37","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","volume":"22","author":"H Gevensleben","year":"2016","unstructured":"Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The Immune Checkpoint Regulator PD-L1 is highly expressed in aggressive primary prostate Cancer. Clin Cancer Res. 2016;22(8):1969\u201377.","journal-title":"Clin Cancer Res"},{"key":"1784_CR38","doi-asserted-by":"crossref","unstructured":"Brito MJ, Sequeira P, Quintas A,Silva I,Silva F, Martins C et al. Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients. Virchows Arch 2023.","DOI":"10.1007\/s00428-023-03580-z"},{"issue":"1","key":"1784_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.21037\/tcr.2019.01.09","volume":"8","author":"C Xue","year":"2019","unstructured":"Xue C, Zhu DCL, Xu Y, Zhang D, et al. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer. Transl Cancer Res. 2019;8(1):111\u20139.","journal-title":"Transl Cancer Res"},{"key":"1784_CR40","doi-asserted-by":"crossref","unstructured":"Yoshida H, Shiraishi K, Kato T. Molecular Pathology of Human Papilloma Virus-negative cervical cancers. Cancers (Basel) 2021; 13(24).","DOI":"10.3390\/cancers13246351"},{"key":"1784_CR41","doi-asserted-by":"crossref","unstructured":"Evans AM, Salnikov M, Gameiro SF, Maleki Vareki S, Mymryk JS. HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct. J Clin Med. 2022; 11(16).","DOI":"10.3390\/jcm11164825"},{"issue":"2","key":"1784_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/imt-2017-0120","volume":"10","author":"N Kuol","year":"2018","unstructured":"Kuol N, Stojanovska L, Nurgali K, Apostolopoulos V. PD-1\/PD-L1 in disease. Immunotherapy. 2018;10(2):149\u201360.","journal-title":"Immunotherapy"},{"issue":"12","key":"1784_CR43","first-page":"1227","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A, Atezolizumab. First Global Approval Drugs. 2016;76(12):1227\u201332.","journal-title":"First Global Approval Drugs"},{"issue":"3 Pt 1","key":"1784_CR44","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","volume":"197","author":"SR Ottenhof","year":"2017","unstructured":"Ottenhof SR, Djajadiningrat RS, de Jong J, Thygesen HH,Horenblas S, Jordanova ES. Expression of programmed death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status. J Urol. 2017;197(3 Pt 1):690\u20137.","journal-title":"J Urol"},{"issue":"6","key":"1784_CR45","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson RH, Dong H, Lohse CM,Leibovich BC,Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757\u201361.","journal-title":"Clin Cancer Res"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-024-01784-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-024-01784-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-024-01784-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:12:40Z","timestamp":1745939560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-024-01784-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1784"],"URL":"https:\/\/doi.org\/10.1007\/s43032-024-01784-5","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"type":"print","value":"1933-7191"},{"type":"electronic","value":"1933-7205"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiments were approved by the ethics committee of Lianyungang No.2 People\u2019s Hospital (Ethics approval number: AF\/SC-08\/01.0-2020X026, approval date: 20200320). All procedures were strictly implemented complying with Declaration of Helsinki. All participants were fully informed of the study objective and provided written informed consents before sampling. The study flow was provided in Supplementary Fig.\u00a0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}